{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:28:36Z","timestamp":1786408116916,"version":"build-2736575974"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      The DOSISPHERE-01 study demonstrated a survival benefit for patients treated with\n                      <jats:sup>90<\/jats:sup>\n                      Y radioembolization using personalised [\n                      <jats:sup>99m<\/jats:sup>\n                      Tc]Tc-MAA guided versus standard dosimetry guided treatment. This ancillary analysis complements DOSISPHERE-01 by reporting post-treatment dosimetry and assessing agreement between predictive ([\n                      <jats:sup>99m<\/jats:sup>\n                      Tc]Tc-MAA) and post-treatment (\n                      <jats:sup>90<\/jats:sup>\n                      Y) absorbed doses.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>\n                      All DOSISPHERE-01 patients with both pre-treatment [\n                      <jats:sup>99m<\/jats:sup>\n                      Tc]Tc-MAA SPECT\/CT and post-treatment\n                      <jats:sup>90<\/jats:sup>\n                      Y imaging were eligible. Multicompartment dosimetry was performed using two segmentation methods: anatomic (MRI\/CT) and count-threshold based (SPECT). Mean normal liver tissue and index-lesion absorbed dose, and dose volume histogram (DVH) metrics were determined using Simplicit\n                      <jats:sup>90<\/jats:sup>\n                      Y (Mirada Medical, Oxford UK). Agreement between [\n                      <jats:sup>99m<\/jats:sup>\n                      Tc]Tc-MAA and\n                      <jats:sup>90<\/jats:sup>\n                      Y absorbed doses was assessed via Bland-Altman and paired-sample analysis, with correlation assessed via linear-regression.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Thirty-seven patients were included: 19 from the personalised arm and 18 from the standard dosimetry arm. Pre- and post-treatment absorbed dose differences were not statistically significant for the index lesion (241\u00a0Gy vs. 229\u00a0Gy,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.15; mean difference 11.9\u00a0Gy; 95% LoA \u2212\u200984.3 to 108.2\u00a0Gy), Perfused Volume Normal Liver Tissue (PVNT) (91\u00a0Gy vs. 99\u00a0Gy,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.14; mean difference \u2212\u20098.2\u00a0Gy; 95% LoA \u2212\u200971.6 to 55.1\u00a0Gy), or DVH metrics (V200, D70, D50) using anatomic segmentation. Corresponding metrics were significantly different using count-threshold segmentation (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05). For both methods, pre- and post-treatment mean index lesion and PVNT absorbed doses, and V200, D70, D50 were strongly correlated (Pearsons Correlation Coefficient\u2009&gt;\u20090.65,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      <jats:sup>90<\/jats:sup>\n                      Y absorbed dose outcomes in the DOSISPHERE-01 study corresponded closely with [\n                      <jats:sup>99m<\/jats:sup>\n                      Tc]Tc-MAA predictive dosimetry, confirming the validity of [\n                      <jats:sup>99m<\/jats:sup>\n                      Tc]Tc-MAA for dosimetry-based treatment planning in this clinical scenario. Agreement was maximised using anatomic segmentation.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00259-026-08079-8","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T23:33:08Z","timestamp":1786404788000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Predictive value of [99mTc]Tc-MAA SPECT\/CT personalised dosimetry in 90Y radioembolization of hepatocellular carcinoma: a DOSISPHERE-01 ancillary study"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-9426-6626","authenticated-orcid":false,"given":"Grace","family":"Keane","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Chalaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Guiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Tselikas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. D","family":"Fowers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Boucher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Garin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X","family":"Palard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. G. E. H.","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,11]]},"reference":[{"key":"8079_CR1","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1200\/EDBK_200939","volume":"38","author":"LY Mak","year":"2018","unstructured":"Mak LY, Cruz-Ram\u00f3n V, Chinchilla-L\u00f3pez P, Torres HA, LoConte NK, Rice JP, Foxhall LE, Sturgis EM, Merrill JK, Bailey HH, M\u00e9ndez-S\u00e1nchez N, Yuen MF, Hwang JP. Global epidemiology, prevention, and management of hepatocellular carcinoma. Am Soc Clin Oncol Educ Book. 2018;38:262\u201379. https:\/\/doi.org\/10.1200\/EDBK_200939.","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"6","key":"8079_CR2","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","volume":"78","author":"AG Singal","year":"2023","unstructured":"Singal AG, Llovet JM, Yarchoan M, Mehta N, Heimbach JK, Dawson LA, Jou JH, Kulik LM, Agopian VG, Marrero JA, Mendiratta-Lala M, Brown DB, Rilling WS, Goyal L, Wei AC, Taddei TH. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023;78(6):1922\u201365. https:\/\/doi.org\/10.1097\/HEP.0000000000000466.","journal-title":"Hepatology"},{"issue":"2","key":"8079_CR3","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.jhep.2024.08.028","volume":"82","author":"European Association for the Study of the Liver","year":"2025","unstructured":"European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma. J Hepatol. 2025;82(2):315\u201374. https:\/\/doi.org\/10.1016\/j.jhep.2024.08.028.","journal-title":"J Hepatol"},{"key":"8079_CR4","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1007\/s00259-019-04340-5","volume":"46","author":"R Salem","year":"2019","unstructured":"Salem R, Padia SA, Lam M, Bell J, Chiesa C, Fowers K, et al. Clinical and dosimetric considerations for Y90: recommendations from an international multidisciplinary working group. Eur J Nucl Med Mol Imaging. 2019;46:1695\u2013704. https:\/\/doi.org\/10.1007\/s00259-019-04340-5.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"8079_CR5","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","volume":"76","author":"M Reig","year":"2022","unstructured":"Reig M, Forner A, Rimola J, Ferrer-F\u00e0brega J, Burrel M, Garcia-Criado \u00c1, Kelley RK, Galle PR, Mazzaferro V, Salem R, Sangro B, Singal AG, Vogel A, Fuster J, Ayuso C, Bruix J. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J Hepatol. 2022;76(3):681\u201393. https:\/\/doi.org\/10.1016\/j.jhep.2021.11.018.","journal-title":"J Hepatol"},{"key":"8079_CR6","doi-asserted-by":"publisher","unstructured":"Reig M, Sanduzzi-Zamparelli M, Forner A, Rimola J, Ferrer-F\u00e0brega J, Burrel M, Garcia-Criado \u00c1, D\u00edaz A, Llarch N, Iserte G, Moll\u00e0 M, Kelley RK, Galle PR, Mazzaferro V, Salem R, Sangro B, Singal AG, Vogel A, Yanagihara TK, Ayuso C, Torres F, Bruix J. BCLC strategy for prognosis prediction and treatment recommendations: The 2026 update. J Hepatol. 2026;84(3):631\u2013654. https:\/\/doi.org\/10.1016\/j.jhep.2025.10.020. Epub 2025 Oct 27. Erratum in: J Hepatol. 2026 Apr 4:S0168-8278(26)00126-1.","DOI":"10.1016\/j.jhep.2025.10.020"},{"issue":"5","key":"8079_CR7","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1007\/s00259-021-05600-z","volume":"49","author":"M Weber","year":"2022","unstructured":"Weber M, Lam M, Chiesa C, Konijnenberg M, Cremonesi M, Flamen P, Gnesin S, Bodei L, Kracmerova T, Luster M, Garin E, Herrmann K. EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. Eur J Nucl Med Mol Imaging. 2022;49(5):1682\u201399. https:\/\/doi.org\/10.1007\/s00259-021-05600-z.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8079_CR8","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s40658-021-00394-3","volume":"8","author":"C Chiesa","year":"2021","unstructured":"Chiesa C, Sjogreen-Gleisner K, Walrand S, et al. EANM dosimetry committee series on standard operational procedures: a unified methodology for 99mTc-MAA pre- and 90Y peri-therapy dosimetry in liver radioembolization with 90Y microspheres. EJNMMI Phys. 2021;8:77. https:\/\/doi.org\/10.1186\/s40658-021-00394-3.","journal-title":"EJNMMI Phys"},{"issue":"2","key":"8079_CR9","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00259-022-05956-w","volume":"50","author":"R Salem","year":"2023","unstructured":"Salem R, Padia SA, Lam M, Chiesa C, Haste P, Sangro B, Toskich B, Fowers K, Herman JM, Kappadath SC, Leung T, Sze DY, Kim E, Garin E. Clinical, dosimetric, and reporting considerations for Y-90 glass microspheres in hepatocellular carcinoma: updated 2022 recommendations from an international multidisciplinary working group. Eur J Nucl Med Mol Imaging. 2023;50(2):328\u201343. https:\/\/doi.org\/10.1007\/s00259-022-05956-w.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"10","key":"8079_CR10","doi-asserted-by":"publisher","first-page":"3340","DOI":"10.1007\/s00259-022-05774-0","volume":"49","author":"M Lam","year":"2022","unstructured":"Lam M, Garin E, Maccauro M, Kappadath SC, Sze DY, Turkmen C, Cantasdemir M, Haste P, Herrmann K, Alsuhaibani HS, Dreher M, Fowers KD, Salem R. A global evaluation of advanced dosimetry in transarterial radioembolization of hepatocellular carcinoma with Yttrium-90: the TARGET study. Eur J Nucl Med Mol Imaging. 2022;49(10):3340\u201352. https:\/\/doi.org\/10.1007\/s00259-022-05774-0.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"13","key":"8079_CR11","doi-asserted-by":"publisher","first-page":"4834","DOI":"10.1007\/s00259-025-07334-8","volume":"52","author":"MGEH Lam","year":"2025","unstructured":"Lam MGEH, Garin E, Fowers KD, Mahvash A, Padia SA, Salem R. The relationship between yttrium-90 glass microspheres specific activity, particle density and treatment outcomes in HCC and mCRC. Eur J Nucl Med Mol Imaging. 2025;52(13):4834\u201346. https:\/\/doi.org\/10.1007\/s00259-025-07334-8.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"8079_CR12","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1055\/s-0041-1736660","volume":"38","author":"G Keane","year":"2021","unstructured":"Keane G, Lam M, de Jong H. Beyond the MAA-Y90 Paradigm: the evolution of radioembolization dosimetry approaches and scout particles. Semin Intervent Radiol. 2021;38(5):542\u201353. https:\/\/doi.org\/10.1055\/s-0041-1736660.","journal-title":"Semin Intervent Radiol"},{"issue":"2","key":"8079_CR13","doi-asserted-by":"publisher","first-page":"255","DOI":"10.2967\/jnumed.111.094235","volume":"53","author":"E Garin","year":"2012","unstructured":"Garin E, Lenoir L, Rolland Y, Edeline J, Mesbah H, Laffont S, Por\u00e9e P, Cl\u00e9ment B, Raoul JL, Boucher E. Dosimetry based on 99mTc-macroaggregated albumin SPECT\/CT accurately predicts tumor response and survival in hepatocellular carcinoma patients treated with 90Y-loaded glass microspheres: preliminary results. J Nucl Med. 2012;53(2):255\u201363. https:\/\/doi.org\/10.2967\/jnumed.111.094235.","journal-title":"J Nucl Med"},{"issue":"1","key":"8079_CR14","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/liv.13220","volume":"37","author":"E Garin","year":"2017","unstructured":"Garin E, Rolland Y, Pracht M, Le Sourd S, Laffont S, Mesbah H, Haumont LA, Lenoir L, Rohou T, Brun V, Edeline J. High impact of macroaggregated albumin-based tumour dose on response and overall survival in hepatocellular carcinoma patients treated with 90 Y-loaded glass microsphere radioembolization. Liver Int. 2017;37(1):101\u201310. https:\/\/doi.org\/10.1111\/liv.13220.","journal-title":"Liver Int"},{"issue":"7","key":"8079_CR15","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1007\/s00259-013-2395-x","volume":"40","author":"E Garin","year":"2013","unstructured":"Garin E, Lenoir L, Edeline J, Laffont S, Mesbah H, Por\u00e9e P, Sulpice L, Boudjema K, Mesbah M, Guillygomarc\u2019h A, Quehen E, Pracht M, Raoul JL, Clement B, Rolland Y, Boucher E. Boosted selective internal radiation therapy with 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept. Eur J Nucl Med Mol Imaging. 2013;40(7):1057\u201368. https:\/\/doi.org\/10.1007\/s00259-013-2395-x.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8079_CR16","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1007\/s00259-024-06920-6","volume":"52","author":"M Lam","year":"2025","unstructured":"Lam M, Garin E, Haste P, et al. Utility of pre-procedural [99mTc]TcMAA SPECT\/CT Multicompartment Dosimetry for Treatment Planning of 90Y Glass microspheres in patients with Hepatocellular Carcinoma: comparison of anatomic versus [99mTc]TcMAA-based Segmentation. Eur J Nucl Med Mol Imaging. 2025;52:744\u201355. https:\/\/doi.org\/10.1007\/s00259-024-06920-6.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8079_CR17","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13550-023-01011-3","volume":"13","author":"M Riveira-Martin","year":"2023","unstructured":"Riveira-Martin M, Akhavanallaf A, Mansouri Z, et al. Predictive value of 99mTc-MAA-based dosimetry in personalized 90Y-SIRT planning for liver malignancies. EJNMMI Res. 2023;13:63. https:\/\/doi.org\/10.1186\/s13550-023-01011-3.","journal-title":"EJNMMI Res"},{"issue":"1","key":"8079_CR18","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S2468-1253(20)30290-9","volume":"6","author":"E Garin","year":"2021","unstructured":"Garin E, Tselikas L, Guiu B, Chalaye J, Edeline J, de Baere T, Assenat E, Tacher V, Robert C, Terroir-Cassou-Mounat M, Mariano-Goulart D, Amaddeo G, Palard X, Hollebecque A, Kafrouni M, Regnault H, Boudjema K, Grimaldi S, Fourcade M, Kobeiter H, Vibert E, Le Sourd S, Piron L, Sommacale D, Laffont S, Campillo-Gimenez B, Rolland Y. DOSISPHERE-01 Study Group. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol. 2021;6(1):17\u201329. https:\/\/doi.org\/10.1016\/S2468-1253(20)30290-9.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"8","key":"8079_CR19","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.2967\/jnumed.112.117614","volume":"54","author":"M Wondergem","year":"2013","unstructured":"Wondergem M, Smits ML, Elschot M, de Jong HW, Verkooijen HM, van den Bosch MA, Nijsen JF, Lam MG. 99mTc-macroaggregated albumin poorly predicts the intrahepatic distribution of 90Y resin microspheres in hepatic radioembolization. J Nucl Med. 2013;54(8):1294\u2013301. https:\/\/doi.org\/10.2967\/jnumed.112.117614.","journal-title":"J Nucl Med"},{"key":"8079_CR20","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s13550-019-0533-6","volume":"9","author":"M Kafrouni","year":"2019","unstructured":"Kafrouni M, Allimant C, Fourcade M, et al. Analysis of differences between 99mTc-MAA SPECT- and 90Y-microsphere PET-based dosimetry for hepatocellular carcinoma selective internal radiation therapy. EJNMMI Res. 2019;9:62. https:\/\/doi.org\/10.1186\/s13550-019-0533-6.","journal-title":"EJNMMI Res"},{"issue":"5","key":"8079_CR21","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.jvir.2016.12.1221","volume":"28","author":"P Haste","year":"2017","unstructured":"Haste P, Tann M, Persohn S, LaRoche T, Aaron V, Mauxion T, Chauhan N, Dreher MR, Johnson MS. Correlation of technetium-99m macroaggregated albumin and yttrium-90 glass microsphere biodistribution in hepatocellular carcinoma: a retrospective review of pretreatment single photon emission CT and posttreatment positron emission tomography\/CT. J Vasc Interv Radiol. 2017;28(5):722\u2013e7301. https:\/\/doi.org\/10.1016\/j.jvir.2016.12.1221.","journal-title":"J Vasc Interv Radiol"},{"issue":"23","key":"8079_CR22","doi-asserted-by":"publisher","first-page":"7245","DOI":"10.3390\/jcm11237245","volume":"11","author":"P d\u2019Abadie","year":"2022","unstructured":"d\u2019Abadie P, Walrand S, Lhommel R, Hesse M, Jamar F. A theranostic approach in SIRT: value of pre-therapy imaging in treatment planning. J Clin Med. 2022;11(23):7245. https:\/\/doi.org\/10.3390\/jcm11237245.","journal-title":"J Clin Med"},{"issue":"2","key":"8079_CR23","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.ijrobp.2018.01.116","volume":"101","author":"KT Chan","year":"2018","unstructured":"Chan KT, Alessio AM, Johnson GE, Vaidya S, Kwan SW, Monsky W, Wilson AE, Lewis DH, Padia SA. Prospective trial using internal pair-production positron emission tomography to establish the yttrium-90 radioembolization dose required for response of hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 2018;101(2):358\u201365. https:\/\/doi.org\/10.1016\/j.ijrobp.2018.01.116.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"8079_CR24","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s00259-023-06416-9","volume":"51","author":"M Lam","year":"2023","unstructured":"Lam M, Garin E, Palard-Novello X, Mahvash A, Kappadath C, Haste P, Tann M, Herrmann K, Barbato F, Geller B, Schaefer N, Denys A, Dreher M, Fowers KD, Gates V, Salem R. Direct comparison and reproducibility of two segmentation methods for multicompartment dosimetry: round robin study on radioembolization treatment planning in hepatocellular carcinoma. Eur J Nucl Med Mol Imaging. 2023;51(1):245\u201357. https:\/\/doi.org\/10.1007\/s00259-023-06416-9.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"8079_CR25","doi-asserted-by":"publisher","first-page":"264","DOI":"10.2967\/jnumed.123.266211","volume":"65","author":"E Garin","year":"2024","unstructured":"Garin E, Tselikas L, Guiu B, Chalaye J, Rolland Y, de Baere T, Assenat E, Tacher V, Palard X, D\u00e9andreis D, Mariano-Goulart D, Amaddeo G, Boudjema K, Hollebecque A, Meerun MA, Regnault H, Vibert E, Campillo-Gimenez B, Edeline J. Long-term overall survival after selective internal radiation therapy for locally advanced hepatocellular carcinomas: updated analysis of DOSISPHERE-01 trial. J Nucl Med. 2024;65(2):264\u20139. https:\/\/doi.org\/10.2967\/jnumed.123.266211.","journal-title":"J Nucl Med"},{"key":"8079_CR26","unstructured":"Centre Eug\u00e8ne Marquis. DOSISPHERES-01 protocol: selective internal radiation therapy for hepatocellular carcinomas with yttrium-90-labelled glass microspheres: optimized dosimetry versus standard dosimetry. Version 5.0. Rennes: Centre Eug\u00e8ne Marquis; 2016. Available from: https:\/\/www.centre-eugene-marquis.fr\/wp-content\/uploads\/2020\/08\/DOSISPHERE-01-trial.pdf"},{"issue":"3","key":"8079_CR27","doi-asserted-by":"publisher","first-page":"477","DOI":"10.2967\/jnumed.108.056036","volume":"50","author":"WE Bolch","year":"2009","unstructured":"Bolch WE, Eckerman KF, Sgouros G, Thomas SR. MIRD pamphlet 21: a generalized schema for radiopharmaceutical dosimetry\u2013standardization of nomenclature. J Nucl Med. 2009;50(3):477\u201384. https:\/\/doi.org\/10.2967\/jnumed.108.056036.","journal-title":"J Nucl Med"},{"issue":"2","key":"8079_CR28","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1177\/096228029900800204","volume":"8","author":"JM Bland","year":"1999","unstructured":"Bland JM, Altman DG. Measuring agreement in method comparison studies. Stat Methods Med Res. 1999;8(2):135\u201360. https:\/\/doi.org\/10.1177\/096228029900800204.","journal-title":"Stat Methods Med Res"},{"key":"8079_CR29","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1007\/s00259-019-04465-7","volume":"47","author":"A Jadoul","year":"2020","unstructured":"Jadoul A, Bernard C, Lovinfosse P, G\u00e9rard L, Lilet H, Cornet O, et al. Comparative dosimetry between (99m)Tc-MAA SPECT\/CT and (90)Y PET\/CT in primary and metastatic liver tumors. Eur J Nucl Med Mol Imaging. 2020;47:828\u201337. https:\/\/doi.org\/10.1007\/s00259-019-04465-7.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"8079_CR30","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.ejmp.2021.07.032","volume":"89","author":"P d\u2019Abadie","year":"2021","unstructured":"d\u2019Abadie P, Walrand S, Hesse M, Amini N, Lhommel R, Sawadogo K, Jamar F. Accurate non-tumoral 99mTc-MAA absorbed dose prediction to plan optimized activities in liver radioembolization using resin microspheres. Phys Med. 2021;89:250\u20137. https:\/\/doi.org\/10.1016\/j.ejmp.2021.07.032.","journal-title":"Phys Med"},{"issue":"11","key":"8079_CR31","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.2967\/jnumed.116.173104","volume":"57","author":"S Gnesin","year":"2016","unstructured":"Gnesin S, Canetti L, Adib S, Cherbuin N, Silva Monteiro M, Bize P, Denys A, Prior JO, Baechler S, Boubaker A. Partition model-based 99mTc-MAA SPECT\/CT Predictive dosimetry compared with 90Y TOF PET\/CT posttreatment dosimetry in radioembolization of hepatocellular carcinoma: a quantitative agreement comparison. J Nucl Med. 2016;57(11):1672\u20138. https:\/\/doi.org\/10.2967\/jnumed.116.173104.","journal-title":"J Nucl Med"},{"key":"8079_CR32","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.ejmp.2020.11.016","volume":"80","author":"J Brosch","year":"2020","unstructured":"Brosch J, Gosewisch A, Kaiser L, Seidensticker M, Ricke J, Zellmer J, Bartenstein P, Ziegler S, Ilhan H, Todica A, B\u00f6ning G. 3D image-based dosimetry for Yttrium-90 radioembolization of hepatocellular carcinoma: Impact of imaging method on absorbed dose estimates. Phys Med. 2020;80:317\u201326. https:\/\/doi.org\/10.1016\/j.ejmp.2020.11.016.","journal-title":"Phys Med"},{"issue":"1","key":"8079_CR33","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13550-019-0485-x","volume":"9","author":"E Jafargholi Rangraz","year":"2019","unstructured":"Jafargholi Rangraz E, Coudyzer W, Maleux G, Baete K, Deroose CM, Nuyts J. Multi-modal image analysis for semi-automatic segmentation of the total liver and liver arterial perfusion territories for radioembolization. EJNMMI Res. 2019;9(1):19. https:\/\/doi.org\/10.1186\/s13550-019-0485-x.","journal-title":"EJNMMI Res"},{"issue":"1","key":"8079_CR34","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s40658-024-00647-x","volume":"11","author":"G Keane","year":"2024","unstructured":"Keane G, van Rooij R, Lam M, Kappadath SC, Kovan B, Leon S, Dreher M, Fowers K, de Jong H. An international phantom study of inter-site variability in Technetium-99m image quantification: analyses from the TARGET radioembolization study. EJNMMI Phys. 2024;11(1):46. https:\/\/doi.org\/10.1186\/s40658-024-00647-x.","journal-title":"EJNMMI Phys"},{"issue":"2","key":"8079_CR35","doi-asserted-by":"publisher","first-page":"e55742","DOI":"10.1371\/journal.pone.0055742","volume":"8","author":"M Elschot","year":"2013","unstructured":"Elschot M, Vermolen BJ, Lam MG, de Keizer B, van den Bosch MA, de Jong HW. Quantitative comparison of PET and Bremsstrahlung SPECT for imaging the in vivo yttrium-90 microsphere distribution after liver radioembolization. PLoS ONE. 2013;8(2):e55742. https:\/\/doi.org\/10.1371\/journal.pone.0055742.","journal-title":"PLoS ONE"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08079-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-08079-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-08079-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T23:33:09Z","timestamp":1786404789000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-08079-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,11]]},"references-count":35,"alternative-id":["8079"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-08079-8","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,11]]},"assertion":[{"value":"14 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethical approval for data collected in the DOSISPHERE-01 study was granted by the Ethics Committee of the University Hospital La Cavalle Blanche (Brest, France) with IRB ID: 2015-A00894-45.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Grace Keane: Is an employee of Boston Scientific. Julia Chalaye: Is a consultant for, and has received honoraria from, Sirtex Medical and Keosys. Boris Guiu: Is a consultant for Roche, AstraZeneca, BMS, Boston Scientific, Guerbet, Terumo, Canon Medical, and Quantum Surgical. Lambros Tselikas: reports personal fees from Boston Scientific, Sirtex, and GE Healthcare; grants from Terumo and the Bristol Myers Squibb Foundation; and non-financial support from GE Healthcare. Kirk D. Fowers: Is an employee of Boston Scientific. Eveline Boucher: Is an employee of Boston Scientific. Etienne Garin: reports receiving a grant, personal fees, and non-financial support from Boston Scientific. Xavier Palard: None declared. Marnix G. E. H. Lam, MD, PhD: Is a consultant for Boston Scientific and Terumo and. He receives research support from Boston Scientific, Terumo and Novartis.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}